PFE Share Price | Pfizer Inc. Stock Analysis & Recommendation

Q: How big is Pfizer Inc.?

As of Jun 18, Pfizer Inc. has a market capitalization of 230,432.79 million, categorizing it as a Large Cap company.As of Jun 18, the sum of net sales for the latest four quarters is 62,463.00 million, while the sum of consolidated net profit for the same period is 7,896.00 million.As of Dec 24, the reporting period shows shareholder's funds at 88,203.00 million and total assets at 213,396.00 million.

Q: What does Pfizer Inc. do?

Overview: Pfizer Inc. is a research-based global biopharmaceutical company engaged in the discovery, development, and manufacture of healthcare products within the Pharmaceuticals & Biotechnology industry, categorized as a Large Cap.Financial Snapshot: Most recent Net Sales: 13,715 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 2,973 Million (Quarterly Results - Mar 2025) Market cap: USD 230,432.79 Million (Large Cap)Key Metrics: P/E: 15.00 Dividend Yield: 416.53% Debt Equity: 0.50 Return on Equity: 16.06% Price to Book: 2.55Contact Details: Address: 235 E 42ND ST, NEW YORK NY: 10017-5703 Tel: 1 212 5732323 Website: https://www.pfizer.com/

Q: Who are in the management team of Pfizer Inc.?

As of March 2022, the management team of Pfizer Inc. includes Dr. Albert Bourla, who serves as the Chairman of the Board and Chief Executive Officer. Other members of the Board of Directors include Mr. Shantanu Narayen as the Lead Independent Director, Dr. Susan Desmond-Hellmann, Mr. Ronald Blaylock, Mr. Joseph Echevarria, and Dr. Scott Gottlieb, all of whom hold the designation of Independent Director.

Q: Is Pfizer Inc. overvalued or undervalued?

As of 29 October 2024, Pfizer Inc. has moved from a risky to a very attractive valuation grade. Given its current P/E ratio of 15, PEG ratio of 0.13, and EV to EBITDA ratio of 11.17, the company appears to be undervalued compared to its peers. For instance, Eli Lilly & Co. has a significantly higher P/E ratio of 40.89, while Merck & Co., Inc. stands at 15.68, indicating that Pfizer's valuation metrics are more favorable.In terms of performance, Pfizer's stock has underperformed relative to the S&P 500 across multiple time frames, with a year-to-date return of -8.97% compared to the S&P 500's 12.22%. This trend reinforces the notion that Pfizer is undervalued, especially considering its strong dividend yield of 428.12% and solid ROE of 16.06%.

Q: Is Pfizer Inc. technically bullish or bearish?

As of 10 October 2025, the technical trend for Pfizer Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. The daily moving averages are also mildly bullish, supporting the overall positive stance. However, the Bollinger Bands show a mixed signal with a mildly bullish weekly view and a bearish monthly perspective. The KST is bullish on the weekly and mildly bullish on the monthly, while the Dow Theory indicates a mildly bullish monthly trend. Despite the mildly bullish indicators, Pfizer's performance has been weak compared to the S&P 500, with a -15.19% return over the past year versus the S&P's 13.36%. Overall, the current technical stance is mildly bullish, but the stock's performance relative to the benchmark raises concerns about its strength.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

7.86 M

Shareholding (Dec 2025)

FII

15.32%

Held by 643 FIIs

DII

58.25%

Held by 418 DIIs

Promoter

0.13%

How big is Pfizer Inc.?

22-Jun-2025

As of Jun 18, Pfizer Inc. has a market capitalization of $230.43 billion, with net sales of $62.46 billion and a net profit of $7.90 billion over the latest four quarters. Shareholder's funds are $88.20 billion, and total assets amount to $213.40 billion.

View full answer

What does Pfizer Inc. do?

22-Jun-2025

Pfizer Inc. is a global biopharmaceutical company focused on the discovery, development, and manufacture of healthcare products. As of March 2025, it reported net sales of $13.7 billion and a market cap of $230.4 billion.

View full answer

Who are in the management team of Pfizer Inc.?

22-Jun-2025

As of March 2022, Pfizer Inc.'s management team includes Dr. Albert Bourla as Chairman and CEO, with Mr. Shantanu Narayen as Lead Independent Director and several Independent Directors: Dr. Susan Desmond-Hellmann, Mr. Ronald Blaylock, Mr. Joseph Echevarria, and Dr. Scott Gottlieb.

View full answer

Is Pfizer Inc. overvalued or undervalued?

20-Sep-2025

As of October 29, 2024, Pfizer Inc. is considered very attractive with a P/E ratio of 15 and a PEG ratio of 0.13, indicating it is undervalued compared to peers like Eli Lilly and Merck, despite underperforming the S&P 500 with a year-to-date return of -8.97%, while offering a strong dividend yield of 428.12% and a solid ROE of 16.06%.

View full answer

Is Pfizer Inc. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Pfizer Inc. shows a mildly bullish technical trend with positive momentum indicators, but its performance has lagged behind the S&P 500, raising concerns about its strength.

View full answer

Compare Pfizer Inc. with Similar Stocks

Merck & Co., Inc.AbbVie, Inc.Johnson & Johnson

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROCE of 16.86%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 2.16 times

The company has declared Positive results for the last 3 consecutive quarters

With ROCE of 12.73%, it has a very attractive valuation with a 1.99 Enterprise value to Capital Employed

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 255,886 Million (Large Cap)

P/E

15.00

Industry P/E

Dividend Yield

285.59%

Debt Equity

0.50

Return on Equity

0.00%

Price to Book

0.00

Revenue and Profits:

Net Sales:

17,557 Million

(Quarterly Results - Dec 2025)

Net Profit:

-1,640 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

5.35%

6 Months

10.54%

1 Year

1.95%

2 Years

-0.22%

3 Years

-31.05%

4 Years

-44.8%

5 Years

-22.24%

Pfizer Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

5.60%

EBIT Growth (5y)

7.73%

EBIT to Interest (avg)

12.68

Debt to EBITDA (avg)

2.16

Net Debt to Equity (avg)

0.50

Sales to Capital Employed (avg)

6,258.25

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

126.47%

Pledged Shares

Institutional Holding

68.35%

ROCE (avg)

16.86%

ROE (avg)

21.23%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.67

EV to EBIT

15.12

EV to EBITDA

11.12

EV to Capital Employed

2.08

EV to Sales

4.47

PEG Ratio

0.07

Dividend Yield

407.26%

ROCE (Latest)

13.77%

ROE (Latest)

18.34%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

No Trend

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 240 Schemes (26.28%)

Foreign Institutions

Held by 643 Foreign Institutions (15.32%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 5.42% vs 13.66% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -146.20% vs 22.29% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "17,557.00",
          "val2": "16,654.00",
          "chgp": "5.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5,476.00",
          "val2": "7,192.00",
          "chgp": "-23.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "711.00",
          "val2": "652.00",
          "chgp": "9.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5,558.00",
          "val2": "-2,117.00",
          "chgp": "-162.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1,640.00",
          "val2": "3,550.00",
          "chgp": "-146.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "215.80%",
          "val2": "332.10%",
          "chgp": "-11.63%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -1.65% vs 6.84% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -3.28% vs 270.67% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "62,579.00",
          "val2": "63,627.00",
          "chgp": "-1.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "23,698.00",
          "val2": "23,496.00",
          "chgp": "0.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2,671.00",
          "val2": "3,091.00",
          "chgp": "-13.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-8,749.00",
          "val2": "-8,006.00",
          "chgp": "-9.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "7,787.00",
          "val2": "8,051.00",
          "chgp": "-3.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "273.40%",
          "val2": "259.10%",
          "chgp": "1.43%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

17,557.00

16,654.00

5.42%

Operating Profit (PBDIT) excl Other Income

5,476.00

7,192.00

-23.86%

Interest

711.00

652.00

9.05%

Exceptional Items

-5,558.00

-2,117.00

-162.54%

Consolidate Net Profit

-1,640.00

3,550.00

-146.20%

Operating Profit Margin (Excl OI)

215.80%

332.10%

-11.63%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 5.42% vs 13.66% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -146.20% vs 22.29% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

62,579.00

63,627.00

-1.65%

Operating Profit (PBDIT) excl Other Income

23,698.00

23,496.00

0.86%

Interest

2,671.00

3,091.00

-13.59%

Exceptional Items

-8,749.00

-8,006.00

-9.28%

Consolidate Net Profit

7,787.00

8,051.00

-3.28%

Operating Profit Margin (Excl OI)

273.40%

259.10%

1.43%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -1.65% vs 6.84% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -3.28% vs 270.67% in Dec 2024

All Annual Results

Company CV

About Pfizer Inc.

Pfizer Inc.

Pharmaceuticals & Biotechnology

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Company Coordinates

Company Details

235 E 42ND ST , NEW YORK NY : 10017-5703

Tel: 1 212 5732323

https://www.pfizer.com/

Registrar Details